The US Food and Drug Administration (FDA) has granted approval for the use of Medtronic’s disposable Simplera Sync sensor with the MiniMed 780G system.
The all-in-one sensor is said to eliminate the need for fingersticks with SmartGuard or overtape, featuring a two-step insertion process.
Go deeper with GlobalData
It adds to Medtronic’s continuous glucose monitoring (CGM) portfolio, offering user flexibility.
According to the company, the MiniMed 780G system features an adaptive algorithm that adjusts the levels of glucose every five minutes, providing 24/7 management.
It claims to be the only system that features Meal Detection technology, delivering additional insulin when required, ensuring glucose levels remain within the target range more frequently, even if users forget to dose insulin or miscalculate carbohydrate intake.
Medtronic noted that the system’s “treat to target” approach and the option to set glucose targets as low as 100mg/dL enable it to mimic non-diabetic glucose levels closely.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIts real-world data indicates that users steadily achieve time in range above 70% with optimal settings, surpassing international targets.
Additionally, the MiniMed 780G claims to be the sole system compatible with an infusion set that continues up to seven days, reducing the frequency of injections by 96% against several daily injections.
The Simplera Sync sensor’s limited US launch is scheduled for the fall of this year. Currently, the MiniMed 780G system is available for use with the Guardian 4 sensor.
Medtronic Diabetes president and executive vice-president Que Dallara said: “We’re committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day.
“Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we’re excited to continue evolving this experience with expanded CGM options —including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the US.”
Last month, the company reported the two-year outcomes from the SMART trial of the Evolut transfemoral transcatheter aortic valve replacement (TAVR) for aortic stenosis (AS) and a small aortic annulus.
